<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538547</url>
  </required_header>
  <id_info>
    <org_study_id>IEC-02/2019-1122</org_study_id>
    <nct_id>NCT04538547</nct_id>
  </id_info>
  <brief_title>Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of Nasopharynx</brief_title>
  <acronym>EARN</acronym>
  <official_title>Randomized Trial to Evaluate Accelerated Radiotherapy in the Management of Locally Advanced Carcinoma of Nasopharynx Using Rapid Arc Image Guided Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed as a two arm randomized trial to evaluate the impact of&#xD;
      accelerated radiotherapy delivered by image guided radiotherapy with rapid arc technique in&#xD;
      carcinoma nasopharynx. The study will evaluate a pure acceleration schedule of 6 fractions&#xD;
      per week with concurrent chemotherapy and without any radiotherapy dose escalation.The&#xD;
      control arm will receive standard chemoradiotherapy using image guided radiotherapy with&#xD;
      rapid arc technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a two arm prospective randomized controlled trial which will be&#xD;
      carried out in the Department of Radiotherapy and Otolaryngology at PGIMER, Chandigarh.&#xD;
&#xD;
      Inclusion criteria&#xD;
&#xD;
        1. Histopathologically proven non keratinizing nasopharangeal cancers.&#xD;
&#xD;
        2. Karnofsky performance status more than 70&#xD;
&#xD;
        3. Stage T3-4, N0-3 patients (as per AJCC 8th edition).&#xD;
&#xD;
        4. Patients willing for informed consent and regular follow up&#xD;
&#xD;
      Exclusion Criteria&#xD;
&#xD;
        1. Keratinizing squamous cell carcinoma&#xD;
&#xD;
        2. Age &gt;70 years&#xD;
&#xD;
        3. Patients who have received previous chemoradiotherapy.&#xD;
&#xD;
        4. Patients with uncontrolled co- morbid conditions like hypertension , diabetes or any&#xD;
           renal impairment&#xD;
&#xD;
      Randomization Patients will be randomized into the two study groups using computer generated&#xD;
      randomization table given below.Total number of patients to be recruited will be 120 and will&#xD;
      be divided into • Study Group A (N= 60): Accelerated Chemoradiotherapy followed by 3 cycles&#xD;
      of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from&#xD;
      Monday to Saturday&#xD;
&#xD;
      • Control Group B (N=60) : Concurrent Chemoradiotherapy followed by 3 cycles adjuvant&#xD;
      chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to&#xD;
      Friday.&#xD;
&#xD;
      Treatment Protocol Clinical evaluation All patients enrolled in the study will undergo a full&#xD;
      clinical examination including a complete head and neck check up Investigations All patients&#xD;
      enrolled in the study will undergo the following investigations&#xD;
&#xD;
        1. Complete Haemogram, Liver Function test &amp; Kidney Function Tests, Blood Sugar&#xD;
&#xD;
        2. Chest X Ray PA View&#xD;
&#xD;
        3. X Ray Soft tissue neck&#xD;
&#xD;
        4. ECG&#xD;
&#xD;
        5. CECT Head and Neck/ Contrast enhanced MRI head and neck&#xD;
&#xD;
        6. Biopsy from primary tumor and FNAC from neck nodes&#xD;
&#xD;
      RADIOTHERAPY Chemoradiotherapy treatment protocol For radiotherapy planning patients will be&#xD;
      immobilized using S type thermoplastic cast &amp; will undergo a planning CT scan with 3mm slice&#xD;
      thickness. The images will be transferred to Eclipse treatment planning system. All patients&#xD;
      will be planned with 6MV photons using 4 arcs with SIB Rapid Arc technique using the dose&#xD;
      prescription given below.&#xD;
&#xD;
      PTV70: 70 Gy in 33 fractions PTV59.4 : 59.4 Gy in 33 fractions PTV50.4: 54 Gy in 33fractions&#xD;
      Concurrent chemotherapy will be given using Cisplatin injection 40mg/m.sq weekly or&#xD;
      100mg/m.sq 3 weekly along with radiotherapy in both the groups. Patients will undergo will&#xD;
      undergo a repeat treatment planning CT scan at the 16th radiotherapy fraction and will be&#xD;
      evaluated for adaptive re-planning.&#xD;
&#xD;
      CHEMOTHERAPY Concurrent : Inj. CDDP 100mg/m2 D1 q 3weekly along with XRT&#xD;
&#xD;
      Adjuvant:&#xD;
&#xD;
      Inj. CDDP 80mg/ m2 D1 q 3 weekly x 3 cycles Inj. 5- FU 1gm/ m2 D1-4&#xD;
&#xD;
      Patients weight will be monitored weekly during treatment.patients will be reviewed at 16th&#xD;
      fraction of treatment. Patients with a weight loss more than 10 % or a decrease of neck&#xD;
      diameter by more than 10% will be evaluated for need for adaptive re-planning.Where indicated&#xD;
      patients will be replanned .&#xD;
&#xD;
      Toxicity &amp; Response Evaluation Patients will be evlautaed weekly for dermatological,&#xD;
      mucositis,Dysphagia, haemtological ,gastrointestinal &amp; constitutional toxicity using Common&#xD;
      Terminology Criteria for adverse effects (CTCAE v3). Overall Response will be evaluated at&#xD;
      end of treatment using Response evaluation criteria for solid Tumors (RECIST ).&#xD;
&#xD;
      Follow up All patients included in the study will be followed up 2 monthly intervals during&#xD;
      the first year, at 3 monthly intervals during the 2-3 years and 6 monthly intervals&#xD;
      thereafter. At each visit a full clinical examination, toxicity grading and disease status&#xD;
      will be evaluated.&#xD;
&#xD;
      Statistics Assuming a significance level of 0.05 and power of 80% a minimum of 110 patients&#xD;
      need to be recruited to detect a difference of about 25% in failure free survival including a&#xD;
      drop out rate of 10%.For statistical analysis data will be entered into SPSSv 20.Treatment&#xD;
      toxicity will be compared between the treatment groups using independent 't' test. Pearson&#xD;
      correlation test and logistic regression analysis will be used to evaluate prognostic&#xD;
      variables.Survival analysis will be done using Kaplan Meir analysis. A p value &lt;0.05 will be&#xD;
      considered as statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare acute treatment related toxicity between the two study groups</measure>
    <time_frame>Within 90 days of completion of treatment</time_frame>
    <description>Patients under study will be monitored for acute toxicity using CTCAEv3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare overall response rates between the two study group</measure>
    <time_frame>At 1 year follow up</time_frame>
    <description>Overall survival will be compared between the study and control group at end of study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Carcinoma, Nasopharyngeal</condition>
  <arm_group>
    <arm_group_label>Accelerated Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Accelerated Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent Chemoradiotherapy followed by 3 cycles adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated Radiotherapy</intervention_name>
    <description>Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday</description>
    <arm_group_label>Accelerated Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Non Accelerated Radiotherapy</intervention_name>
    <description>Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday</description>
    <arm_group_label>Non Accelerated Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histopathologically proven non keratinizing nasopharangeal cancers.&#xD;
&#xD;
          2. Karnofsky performance status more than 70&#xD;
&#xD;
          3. Stage T3-4, N0-3 patients (as per AJCC 8th edition).&#xD;
&#xD;
          4. Patients willing for informed consent and regular follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Keratinizing squamous cell carcinoma&#xD;
&#xD;
          2. Age &gt;70 years&#xD;
&#xD;
          3. Patients who have received previous chemoradiotherapy.&#xD;
&#xD;
          4. Patients with uncontrolled co- morbid conditions like hypertension , diabetes or any&#xD;
             renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AMIT BAHL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PGIMER CHANDIGARH INDIA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AMIT BAHL, MD</last_name>
    <phone>+916283774431</phone>
    <email>dramitbahl@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ANURAG VERMA, MSc</last_name>
    <phone>+919996986978</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AMIT BAHL, MD</last_name>
      <phone>+916283774431</phone>
      <email>dramtbahl@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Lee AW, Sze WM, Yau TK, Yeung RM, Chappell R, Fowler JF. Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity. Radiother Oncol. 2001 Feb;58(2):121-30.</citation>
    <PMID>11166862</PMID>
  </reference>
  <reference>
    <citation>Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6.</citation>
    <PMID>25957714</PMID>
  </reference>
  <reference>
    <citation>Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017 Sep;18(9):1221-1237. doi: 10.1016/S1470-2045(17)30458-8. Epub 2017 Jul 27. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.</citation>
    <PMID>28757375</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 30, 2020</last_update_submitted>
  <last_update_submitted_qc>August 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>AMIT BAHL</investigator_full_name>
    <investigator_title>ADDITIONAL PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>altered fractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

